The use of SGLT2 inhibitors was not associated with a clear increase in overall UTI risk among patients with RA and diabetes.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

Panelists discuss how SGLT2 inhibitors evolved from diabetes medications to become foundational heart failure therapy with class I recommendations across the ejection fraction spectrum, providing ...

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

Please provide your email address to receive an email when new articles are posted on . Treatment with sodium-glucose cotransporter-2 inhibitors for type 2 diabetes may reduce the risk for rheumatoid ...

Please provide your email address to receive an email when new articles are posted on . Treatment with SGLT2 inhibitors was associated with decreased mortality but increased incidence of lupus ...

GLP-1RA and SGLT2 inhibitor combination therapy was associated with better cardiorenal outcomes than monotherapy among patients with type 2 diabetes. The cardiorenal benefits of sodium-glucose ...

Patients prescribed SGLT2 inhibitors less likely to exhibit nodule growth and to undergo a surgical intervention. HealthDay News — For patients with diabetes and early-stage pulmonary malignancies, ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an ...

SGLT2 inhibitors linked to lower hormone therapy failure in prostate cancer. Learn more about their potential role in improving treatment outcomes.